Eli Lilly continues to dominate the obesity market with Zepbound and Orforglipron, leading JPMorgan to see it as a top pick ...

LLY breaks above its 50-day average as Mounjaro and Zepbound drive revenues. Is this a new entry point for investors?

Eli Lilly's experimental obesity drug, eloralintide, helped some patients lose 11.5% of their body weight at 12 weeks in an ...

Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company, The Home Depot and ...

Wegovy maker Novo Nordisk is moving its investigational amycretin asset into late-stage weight loss trials starting early ...

A new study found that weight-loss medications like Ozempic and Mounjaro are not as effective in a “real-world” setting ...

England's National Health Service said Friday it is the first health system in the world to offer a targeted blood cancer ...

A new study from UCLA Health suggests COVID-19 vaccines may protect patients from severe kidney damage. The study found ...

Receding floodwaters that submerged homes days before left the residents of Mthatha, South Africa, helpless. They watched the bodies of their families and ...

Authorities in Kenya have arrested a senior police officer responsible for the cell where a blogger died, leading to ...

Jewelry shops are seeing an increase in business due to the popularity of weight loss drugs. Women using drugs, like Ozempic, are heading to jewelers in droves to size down their rings. Van Guilder’s ...